Leadership preparing for a possible pandemic of swine
influenza vaccine and bulk buying drugs for the treatment of
this disease.

Pharmaceutical company GlaxoSmithKline acknowledges that arose due to
the threat of a pandemic panic, she managed to significantly increase their revenues.
Already in September, GlaxoSmithKline offers the world's first vaccine against swine
influenza. The UK government has ordered 60 million doses of the drug.
Many countries are also produced by GlaxoSmithKline buy drug Relenza,
which helps to cope with the symptoms of the disease. This means that
Glaxo, like many other pharmaceutical companies do not earn badly
for swine flu. From the beginning, this concern has sold British Medical
drugs worth 3 billion pounds. The head of GlaxoSmithKline, Andrew Witty
reported that the company is ready to fight the pandemic. According to him, thanks to
investment, which over the past three and a half years were
billion pounds, the plant may soon increase production.
The pharmaceutical company Roche Holding AG, in turn, claimed
to start programs to reduce the price of its drug Tamiflu, also used
for the treatment of swine influenza in developing countries by half, and allowed
pay money for it for several years. Medicine will be
5 to 6 euros, while the standard price per pack of Tamiflu
12 euros. The program will be open to 70 members of the Global
Alliance for Vaccines and Immunization. The exception is India, which
sold the drug analogue Tamiflu. As previously reported, the cost of potential
Market vaccination against swine influenza is estimated at 10-20 billion dollars.

Share This Post: